By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen today said that it has been named a certified service provider for Ion Torrent's Personal Genome Machine.

Austin, Texas-based Asuragen will use the Ion Torrent platform to provide targeted DNA mutation analysis of tumor samples to identify known and de novo mutations within FFPE and FNA specimens. The services will include both Asuragen's SuraSeq custom cancer panels and the Ion AmpliSeq cancer panel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.